Girinimbine
Based on 1 Customer Validation
Girinimbine (Girinimbin) is a carbazole alkaloid with a variety of biological effects. Girinimbine can induce apoptosis, and has antitrypanosomal, antiplatelet activity, antibacterial activity, anti-inflammatory, antioxidant and antitumor activities.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.23%
- CAS 番号: 23095-44-5
- 分子式: C18H17NO
- 分子量:263.33
-
保管条件:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Parasite アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
>50 μM
Compound: Girinimbine
|
Anticancer activity against human A2780 cells by MTT assay
Anticancer activity against human A2780 cells by MTT assay
|
[PMID: 33316408] |
| A-431 | IC50 |
>50 μM
Compound: Girinimbine
|
Anticancer activity against human A431 cells by MTT assay
Anticancer activity against human A431 cells by MTT assay
|
[PMID: 33316408] |
| Bel-7402 | IC50 |
>50 μM
Compound: Girinimbine
|
Anticancer activity against human H7402 cells by MTT assay
Anticancer activity against human H7402 cells by MTT assay
|
[PMID: 33316408] |
| BGC-823 | IC50 |
>50 μM
Compound: Girinimbine
|
Anticancer activity against human BGC-823 cells by MTT assay
Anticancer activity against human BGC-823 cells by MTT assay
|
[PMID: 33316408] |
| HCT-8 | IC50 |
34.69 μM
Compound: Girinimbine
|
Anticancer activity against human HCT-8 cells by MTT assay
Anticancer activity against human HCT-8 cells by MTT assay
|
[PMID: 33316408] |
| HeLa | IC50 |
>50 μM
Compound: Girinimbine
|
Anticancer activity against human HeLa cells by MTT assay
Anticancer activity against human HeLa cells by MTT assay
|
[PMID: 33316408] |
| HepG2 | IC50 |
>160 μM
Compound: 7
|
Growth inhibition of human HepG2 cells after 48 hrs by WST-8 based CCK8 assay
Growth inhibition of human HepG2 cells after 48 hrs by WST-8 based CCK8 assay
|
[PMID: 22093759] |
| KB | IC50 |
263.1 μM
Compound: 7
|
Cytotoxicity against human KB cells by resazurin reduction assay
Cytotoxicity against human KB cells by resazurin reduction assay
|
[PMID: 22482432] |
| KB | IC50 |
7.02 μM
Compound: 5
|
Cytotoxicity against human KB cells by resazurin microplate assay
Cytotoxicity against human KB cells by resazurin microplate assay
|
[PMID: 21302964] |
| KETR3 | IC50 |
>50 μM
Compound: Girinimbine
|
Anticancer activity against human KETR3 cells by MTT assay
Anticancer activity against human KETR3 cells by MTT assay
|
[PMID: 33316408] |
| MCF7 | IC50 |
28.8 μM
Compound: 7
|
Cytotoxicity against human MCF7 cells by resazurin reduction assay
Cytotoxicity against human MCF7 cells by resazurin reduction assay
|
[PMID: 22482432] |
| MCF7 | IC50 |
49.76 μM
Compound: Girinimbine
|
Anticancer activity against human MCF7 cells by MTT assay
Anticancer activity against human MCF7 cells by MTT assay
|
[PMID: 33316408] |
| NCI-H187 | IC50 |
22.37 μM
Compound: 5
|
Cytotoxicity against human NCI-H187 by resazurin microplate assay
Cytotoxicity against human NCI-H187 by resazurin microplate assay
|
[PMID: 21302964] |
| NCI-H187 | IC50 |
58.9 μM
Compound: 7
|
Cytotoxicity against human NCI-H187 cells by resazurin reduction assay
Cytotoxicity against human NCI-H187 cells by resazurin reduction assay
|
[PMID: 22482432] |
| NCI-H460 | IC50 |
27.01 μM
Compound: Girinimbine
|
Anticancer activity against human H460 cells by MTT assay
Anticancer activity against human H460 cells by MTT assay
|
[PMID: 33316408] |
| SW1990 | IC50 |
>50 μM
Compound: Girinimbine
|
Anticancer activity against human SW1990 cells by MTT assay
Anticancer activity against human SW1990 cells by MTT assay
|
[PMID: 33316408] |
| Vero | IC50 |
>200 μM
Compound: 5
|
Cytotoxicity against african green monkey Vero cells by green fluorescent protein microplate assay
Cytotoxicity against african green monkey Vero cells by green fluorescent protein microplate assay
|
[PMID: 21302964] |
体外実験
Girinimbine (1-400 µM; 24-72 h) decreases the viability of HepG2 cells in 24, 48 and 72 h with IC50 values of 61 µM, 56 µM, and 40 µM respectively. Girinimbine (10-100 µM; 24-48 h) increase of LDH leakage in both concentration- and time-dependent manner in HepG2 cells[1].
Girinimbine (56 µM; 24-48 h) treatment results in DNA fragmentation and elevates levels of caspase-3 in HepG2 cells[1].
HepG2 cells[1].
Girinimbine (56 µM; 12-48 h) treatment also displays a time-dependent accumulation of the Sub-G0/G1 peak (hypodiploid) and caused G0/G1-phase arrest[1].
Girinimbine shows a potent antitrypanosomal activitywith an IC50 value of 10.16 µg/mL[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepG2 cells
-
Concentration:1 µM, 10 µM, 50 µM, 100 µM, 200 µM
-
Incubation Time:24 h, 48 h and 72 h
-
Result:Inhibited the proliferation of HepG2 cells in vitro in a dose- and time-dependent manner.
-
Cell Line:HepG2 cells
-
Concentration:56 µM
-
Incubation Time:24 h, 48 h
-
Result:Showed typical morphological features of apoptosis.
-
Cell Line:HepG2 cells
-
Concentration:56 µM
-
Incubation Time:12 h, 24 h, 48 h
-
Result:Induced G0/G1-phase arrest in HepG2 cells.
体内実験
In vivo in zebrafish embryos, Girinimbine (20 μg/mL; 24 hours) shows significant distribution of apoptotic cells in embryos[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male ICR mice (25-35 g) treated with carrageenan[2]
-
Dosage:10 mg/kg, 30 mg/kg, and 100 mg/kg
-
Administration:Orally gavage; once
-
Result:Helped limit total leukocyte migration, and reduced pro-inflammatory cytokine levels in the peritoneal fluid.
化学情報
-
CAS 番号 23095-44-5
-
性状 Solid
-
分子量 263.33
-
分子式 C18H17NO
-
Color Off-white to light yellow
-
SMILES
CC(OC1=C(C)C=C23)(C)C=CC1=C3NC4=C2C=CC=C4
-
別名
Girinimbin
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
純度とドキュメンテーション
-
データシート (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Suvitha Syam, et al. The growth suppressing effects of girinimbine on HepG2 involve induction of apoptosis and cell cycle arrest. Molecules. 2011 Aug 23;16(8):7155-70. [Content Brief]
[2]. Venoos Iman, et al. Anticancer and anti-inflammatory activities of girinimbine isolated from Murraya koenigii. Drug Des Devel Ther. 2016 Dec 28;11:103-121. [Content Brief]
[3]. H O Dyary, et al. Antitrypanosomal and cytotoxic activities of botanical extracts from Murraya koenigii (L.) and Alpinia mutica Roxb. Trop Biomed. 2019 Mar 1;36(1):94-102. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)